A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

Schwarze, J. K. (Presenter), Tijtgat, J. (Contributor), Awada, G. (Contributor), Cras, L. (Contributor), Dufait, I. (Contributor), Forsyth, R. (Contributor), Tuyaerts, S. (Contributor), Neyns, B. (Contributor)

Activiteit: Talk or presentation at a conference


Mini oral presentation in the "Investigational Immunotherapy" session
Periode17 sep 2021
EvenementstitelESMO Congress 2021
LocatieParis, France
Mate van erkenningInternational